<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037101</url>
  </required_header>
  <id_info>
    <org_study_id>07-01-1896</org_study_id>
    <nct_id>NCT01037101</nct_id>
  </id_info>
  <brief_title>D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights</brief_title>
  <official_title>D-Cycloserine as Enhancer of One-Session Treatment for Phobia of Heights in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAMC Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>West Virginia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Charleston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CAMC Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the effects of D-Cycloserine (DCS) on fear reduction in patients&#xD;
      diagnosed with phobia of heights (acrophobia) undergoing one session of three hours of&#xD;
      virtual reality exposure therapy (VRET) or in vivo exposure therapy (IVET).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impact of D-Cycloserine on Virtual Reality Exposure Therapy (VRET) and In Vivo Exposure&#xD;
      Therapy (IVET) for phobia of heights (acrophobia) will be tested using a randomized,&#xD;
      double-blind, placebo-controlled trial. Eighty participants will be randomly assigned to one&#xD;
      of the four treatment conditions: one-session VRET (3 hours) and 50 mg D-Cycloserine (VR-OST&#xD;
      + DCS, N1=20); one-session VRET (3 hours) and placebo (VR-OST + Pl, N2=20); one-session IVET&#xD;
      (3 hours) and placebo (IV + Pl, N3=20); or one-session IVET (3 hours) and 50 mg&#xD;
      D-Cycloserine, (IV + DCS, N4=20). For twenty participants (5 from each group) the treatment&#xD;
      will be delayed for three weeks and an additional assessment will be conducted as they will&#xD;
      comprise a Wait List (WL) control group. Behavioral, cognitive and physiological changes in&#xD;
      acrophobia will be assessed at pre-treatment, post-waitlist, post-treatment and 3 months&#xD;
      follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific Phobia (acrophobia) diagnosis based on Anxiety Disorders Interview Schedule-IV (ADIS-IV)</measure>
    <time_frame>One week post-treatment and 3 months folow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physiological responses to phobia-related stimuli, percentage of steps completed and Subjective Units of Distress during a Behavioral Avoidance Test (BAT)</measure>
    <time_frame>One week post-treatment and 3 months follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Height Phobia</condition>
  <arm_group>
    <arm_group_label>IVET+DCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VRET+DCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VRET+Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IVET+Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait-List</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>3 weeks Wait-List</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>In Vivo Exposure Therapy</intervention_name>
    <description>Three hours of exposure therapy in a high place</description>
    <arm_group_label>IVET+DCS</arm_group_label>
    <arm_group_label>IVET+Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Virtual Reality Exposure Therapy</intervention_name>
    <description>Three hours of exposure therapy using a virtual reality system</description>
    <arm_group_label>VRET+DCS</arm_group_label>
    <arm_group_label>VRET+Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-Cycloserine</intervention_name>
    <description>50 mg of DCS administered 30 minutes before the session</description>
    <arm_group_label>IVET+DCS</arm_group_label>
    <arm_group_label>VRET+DCS</arm_group_label>
    <other_name>Seromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg placebo administered 30 minutes before the session</description>
    <arm_group_label>IVET+Placebo</arm_group_label>
    <arm_group_label>VRET+Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 65 years&#xD;
&#xD;
          -  Men and women&#xD;
&#xD;
          -  Diagnosis of acrophobia based on a clinical interview (ADIS-IV)&#xD;
&#xD;
          -  Must sign an informed consent document after complete explanation of the study&#xD;
             documenting that they understand the purpose of the study, procedures to be&#xD;
             undertaken, possible benefits, potential risks, and are willing to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional&#xD;
             disorders; organic brain syndrome, cognitive dysfunction that could interfere with&#xD;
             capacity to engage in therapy;&#xD;
&#xD;
          -  A history of substance or alcohol dependence (other than nicotine) in the last 6&#xD;
             months or otherwise unable to commit to refraining from alcohol use during the period&#xD;
             of study participation.&#xD;
&#xD;
          -  Patients with significant suicidal ideation or who have enacted suicidal behaviors&#xD;
             within 6 months prior to intake will be excluded from study participation and referred&#xD;
             for appropriate services.&#xD;
&#xD;
          -  Patients must be off concurrent anxiolytics and beta blockers and on a stable dose of&#xD;
             antidepressant medication for at least 3 weeks prior to initiation of randomized&#xD;
             treatment.&#xD;
&#xD;
          -  Patients receiving medication that might interfere with study medication (medication&#xD;
             that might lower seizure threshold: meperidine or antibiotics in high dosage:&#xD;
             penicillins, cephalosporins, amphotericin and imipenem),&#xD;
&#xD;
          -  Patients with a current or past history of seizures&#xD;
&#xD;
          -  Pregnant women, lactating women, and women of childbearing potential who are not using&#xD;
             medically accepted effective methods of contraception or abstinence&#xD;
&#xD;
          -  Patients with a history of renal insufficiency (creatinine clearance less than 60&#xD;
             mL/min) or liver insufficiency&#xD;
&#xD;
          -  Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing&#xD;
             psychotherapy of any duration specifically targeting phobias&#xD;
&#xD;
          -  Patients unable to understand study procedures and participate in the informed consent&#xD;
             process.&#xD;
&#xD;
          -  Other serious medical illnesses (e.g., cardiovascular, liver, kidney, respiratory,&#xD;
             endocrine, neurologic, or blood-related diseases),&#xD;
&#xD;
          -  Inability to tolerate wearing the Virtual Reality Head Mounted Display,&#xD;
&#xD;
          -  If patients refuse the study medication&#xD;
&#xD;
          -  Any allergic reactions to D-Cycloserine by history&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristian Sirbu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMC Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Virginia University School of Medicine Charleston Division</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristian Sirbu, Ph.D.</last_name>
      <phone>304-388-1024</phone>
      <email>cristian.sirbu@camc.org</email>
    </contact>
    <contact_backup>
      <last_name>Patrick L Kerr, Ph.D.</last_name>
      <phone>304.388.1033</phone>
      <email>patrick.kerr@camc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>December 18, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <last_update_submitted>October 11, 2013</last_update_submitted>
  <last_update_submitted_qc>October 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CAMC Health System</investigator_affiliation>
    <investigator_full_name>Crisitian Sirbu, PhD</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>acrophobia</keyword>
  <keyword>virtual reality</keyword>
  <keyword>exposure therapy</keyword>
  <keyword>In Vivo Exposure Therapy plus D-Cycloserine</keyword>
  <keyword>In Vivo Exposure Therapy plus Placebo</keyword>
  <keyword>Virtual Reality Exposure Therapy plus D-Cycloserine</keyword>
  <keyword>Virtual Reality Exposure Therapy plus Placebo</keyword>
  <keyword>Wait-List</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phobic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

